Claims for Patent: 9,556,182

Summary for Patent: 9,556,182

Title:	Inhibitors of Bruton\'s tyrosine kinase
Abstract:	Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Buggy; Joseph J. (Mountain View, CA), Loury; David (Incline Village, NV), Chen; Wei (Fremont, CA)
Assignee:	Pharmacylics LLC (Sunnyvale, CA)
Application Number:	14/794,685
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,556,182
Patent Claims:	1. A method for treating a B-cell proliferative disorder or a mast cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (B5): ##STR00127## wherein: Y is a 4-, 5-, 6-membered cycloalkylene ring; each R.sub.a is independently H, halogen, --CF.sub.3, --CN, --NO.sub.2, OH, NH.sub.2, -L.sub.a-(substituted or unsubstituted alkyl), -L.sub.a-(substituted or unsubstituted alkenyl), -L.sub.a-(substituted or unsubstituted heteroaryl), or -L.sub.a-(substituted or unsubstituted aryl), wherein L.sub.a is a bond, O, S, --S(.dbd.O), --S(.dbd.O).sub.2, NH, C(O), CH.sub.2, --NHC(O)O, --NHC(O), or --C(O)NH; G is ##STR00128## R.sub.2 is selected from H, lower alkyl, and substituted lower alkyl; R.sub.6, R.sub.7 and R.sub.8 are independently selected from H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; and R.sub.12 is H or lower alkyl; or Y and R.sub.12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, further comprising administering to the subject a therapeutically effective amount of an anticancer agent, wherein the compound of Formula (B5) and the anticancer agent are administered simultaneously or sequentially. 3. The method of claim 2, wherein the anticancer agent is an alkylating agent, vinca alkaloid, epipodophyllotoxin, angiogenesis inhibitor, adrenocorticosteroid, progestin, estrogen, antiestrogen, androgen, antiandrogen, or gonadotropin releasing hormone analog, or a combination thereof. 4. The method of claim 2, wherein the anticancer agent is bortezomib, carmustine, carboplatin, cisplatin, cyclophosphamide, chlorambucil, ifosfamide, doxorubicin, vincristine, etoposide, gemcitabine, fludarabine phosphate, fluorouracil, imatinib, geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), flavopiridol, bortezomib, trastuzumab, methotrexate, melphalan, prednisone, rituximab, dexamethasone, cytarabine, paclitaxel, amrubicin, or azacitidine, or a combination thereof. 5. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is a mast cell malignancy. 6. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is a lymphoma. 7. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is chronic lymphocytic leukemia. 8. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is diffuse large B-cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, plasma cell myeloma, plasmacytoma, Burkitt's lymphoma/leukemia, or lymphomatoid granulomatosis. 9. The method of claim 1, wherein G is ##STR00129## 10. The method of claim 9, wherein R.sub.6, R.sub.7, and R.sub.8 are H. 11. The method of claim 9, wherein R.sub.7 and R.sub.8 are H; and R.sub.6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl. 12. The method of claim 11, wherein R.sub.6 is lower alkyl. 13. The method of claim 11, wherein R.sub.6 is substituted lower alkyl. 14. The method of claim 9, wherein R.sub.6 and R.sub.8 are H; and R.sub.7 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl. 15. The method of claim 14, wherein R.sub.7 is lower alkyl. 16. The method of claim 14, wherein R.sub.7 is substituted lower alkyl. 17. The method of claim 1, wherein G is ##STR00130## 18. The method of claim 17, wherein R.sub.6 is H. 19. The method of claim 17, wherein R.sub.6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl. 20. The method of claim 19, wherein R.sub.6 is lower alkyl. 21. The method of claim 19, wherein R.sub.6 is substituted lower alkyl. 22. The method of claim 1, wherein Y and R.sub.12 taken together form a 6-membered heterocyclic ring.

Details for Patent 9,556,182

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-03-28
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2027-03-28
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-03-28
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-03-28
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2027-03-28